Skip to main content
. 2017 May 22;7:2239. doi: 10.1038/s41598-017-02527-0

Table 2.

Time difference between survival and death patients within tests and therapies after PQ poisoning.

Variables Survival Patients (mean ± SD, hrs) t/χ 2 value P value
Yes No
The first appearance of AKI
 Stage I 7.25 ± 1.96 3.78 ± 1.24 4.326 0.036
 Stage II 35.39 ± 8.14 27.65 ± 9.33 3.081 0.058
 Stage III 39.61 ± 12.42 34.30 ± 13.28 2.764 0.092
 The first appearance of pulmonary lesions (Y/N) 203.13 ± 50.61 168.57 ± 46.75 4.029 0.024
Gastric lavage (Y/N) 2.21 ± 1.07 3.37 ± 2.49 2.062 0.106
Cathartic (Y/N) 3.03 ± 2.94 5.16 ± 3.15 1.331 0.173
Emetic (Y/N) 1.28 ± 1.09 3.26 ± 1.53 1.824 0.152
Glucocorticoid
 TG1 3.01 ± 2.05 3.52 ± 2.49 2.797 0.005
 TG2 27.63 ± 6.35 29.01 ± 7.32 2.515 0.012
 TG3 50.26 ± 7.17 51.73 ± 8.29 2.370 0.018
 TG4 73.35 ± 7.35 74.22 ± 8.48 1.374 0.170
 TG5 96.85 ± 8.79 97.93 ± 9.25 1.491 0.136
 TG6 120.72 ± 9.93 121.69 ± 9.26 1.255 0.210
 TG7 143.85 ± 10.78 144.36 ± 11.19 0.581 0.563
Immunosuppressor
 TI1 3.55 ± 2.24 3.93 ± 2.68 −1.923 0.055
 TI2 27.41 ± 7.36 28.76 ± 10.57 −1.769 0.063
 TI3 52.01 ± 7.84 51.87 ± 10.96 0.601 0.548
 TI4 75.63 ± 8.07 75.15 ± 11.27 1.886 0.060
 TI5 98.74 ± 8.12 98.93 ± 11.35 0.732 0.465
 TI6 122.26 ± 8.52 122.35 ± 11.48 0.320 0.749
 TI7 145.39 ± 9.01 145.52 ± 11.94 0.407 0.684
 TI8 168.18 ± 9.37 168.45 ± 12.27 0.777 0.437
Haemoperfusion
 TH1 3.85 ± 3.09 4.53 ± 4.10 2.348 0.020
 TH2 23.74 ± 13.21 27.02 ± 14.52 2.948 0.003
 TH3 46.63 ± 13.58 46.63 ± 13.58 2.269 0.024
 TH4 69.87 ± 14.13 72.08 ± 15.21 1.877 0.061
 TH5 93.15 ± 14.92 95.28 ± 16.03 1.715 0.087
 TH6 116.48 ± 15.51 118.75 ± 16.89 1.746 0.081
 TH7 139.07 ± 16.14 141.69 ± 17.53 1.939 0.053
 TH8 162.37 ± 17.08 163.59 ± 18.04 0.865 0.387
 TH9 185.74 ± 17.76 186.32 ± 18.69 0.396 0.692
 TH10 208.06 ± 18.34 209.81 ± 19.10 1.164 0.245

AKI: Acute kidney injury. TG1, TG2…TG7: the first, second…seven time use of glucocorticoid. TI1, TI2…TI8: the first, second…eight time use of immunosuppressor. TH1, TH2…TH10: the first, second…ten time use of haemoperfusion.